ROCHE
ActiveSummary
ROCHE has been active since 1924 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €64.5m and a net result of €8.7m. Equity is growing by ~5.7% per year across the filed fiscal years. Its solvency ranks better than 40% of 65 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability61▲+2
Solvency64▲+10
Growth71▼-2
Track record100
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2,000,000 at 30 days acceptable
Liquidity ample (current ratio 1.62 against 1.4 in 2024; short-term debt: 59.3% of total assets), but 60.9% of the assets are financed with debt.
Credit check for your own amount and term
Open the credit simulator : see how the verdict changes with amount, term and advance.
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
39.1%
Return on assets
5.3%
Age of the figures
9 mo
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 09-06-2026, 52 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
52 d early
2024
44 d early
2023
188 d late
2022
83 d early
2021
93 d early
2020
94 d early
2019
85 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 38 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
26-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit simulator What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file What other support did companies like this one receive, and it did not?Subsidy mirror How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, full schema
In the rankings
#1 oldest company in Belgium, Pharmaceuticals sector#2 company by total assets in the Brussels-Capital Region, Pharmaceuticals sector#2 company by equity in Anderlecht, Manufacturing sector
Turnover
€448.8m▼ 0.5%
2024 · €451.2m
EBIT margin
2.8%▲ 0.3pp
2024 · 2.5%
Net result
€8.7m▲ 10.9%
2024 · €7.9m
Working capital
€60.6m▲ 16.4%
2024 · €52.0m
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line2018202320242025
Turnover€271.0m-€421.0m-€451.2m▲ 7.2%€448.8m▼ 0.5%
Operating result€4.1m-€10.6m-€11.2m▲ 6.0%€12.4m▲ 11.1%
Net result€2.3m-€8.9m-€7.9m▼ 11.1%€8.7m▲ 10.9%
EBIT margin1.5%-2.5%-2.5%=2.8%▲ 0.3pp
Equity€41.8m-€69.8m-€55.7m▼ 20.2%€64.5m▲ 15.7%
Total assets€101.9m-€189.3m-€190.4m▲ 0.6%€164.7m▼ 13.5%
Debt€45.0m-€114.7m-€130.1m▲ 13.4%€97.7m▼ 24.9%
Working capital€45.2m-€65.6m-€52.0m▼ 20.7%€60.6m▲ 16.4%
Staff (FTE)160.9-144.6-132.6▼ 8.3%122.7▼ 7.5%
Result per fiscal year
Operating resultNet result
The operating result has risen two years in a row; 2025 is 11% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €164.7m
Fixed assets
€6.4m ▼ 22.5%
Current assets
€158.3m ▼ 13.1%
Equity and liabilities €164.7m
Equity
€64.5m ▲ 15.7%
Provisions
€2.5m ▼ 45.1%
Debt
€97.7m ▼ 24.9%
Debt's share of the balance-sheet total falls from 68.3% to 59.3%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€13.2m▲
2024 · €12.0m
Cash flow
€9.5m▲
2024 · €8.6m
Current ratio
1.62▲
2024 · 1.40
Quick ratio
1.05▲
2024 · 0.86
Debt to equity
1.52▼
2024 · 2.34
ROE
13.6%▼
2024 · 14.2%
ROA
5.3%▲
2024 · 4.1%
Interest coverage
237.78▲
2024 · 200.31
Debt ≤ 1 year
€97.7m▼
2024 · €130.1m
Income taxes
€2.8m▼
2024 · €3.4m
Staff costs
€28.1m▼
2024 · €28.5m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2018 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Operating income70/76A | - | €442.7m | €472.5m | €471.9m | ▼ 0.1% |
| Turnover70 | €271.0m | €421.0m | €451.2m | €448.8m | ▼ 0.5% |
| Other operating income74 | - | €21.7m | €21.3m | €23.0m | ▲ 8.1% |
| Non-recurring operating income76A | - | - | - | €17,162 | - |
| Operating charges60/66A | - | €432.2m | €461.3m | €459.4m | ▼ 0.4% |
| Goods for resale, raw materials and consumables60 | - | €261.9m | €260.8m | €259.9m | ▼ 0.3% |
| Purchases600/8 | - | €267.2m | €282.8m | €247.2m | ▼ 12.6% |
| Change in stocks: decrease (increase)609 | - | -€5.3m | -€22.1m | €12.8m | ▲ 158% |
| Services and other goods61 | - | €19.6m | €19.7m | €21.1m | ▲ 7.0% |
| Remuneration, social security and pensions62 | - | €27.7m | €28.5m | €28.1m | ▼ 1.4% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €796,680 | €791,234 | €753,150 | €728,875 | ▼ 3.2% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | -€2.3m | €572,248 | €1.2m | ▲ 117% |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | -€2.1m | -€122,363 | -€2.1m | ▼ 1,592% |
| Other operating charges640/8 | - | €126.5m | €151.1m | €148.6m | ▼ 1.7% |
| Non-recurring operating charges66A | - | - | - | €1.8m | - |
| Operating profit (loss)9901 | €4.1m | €10.6m | €11.2m | €12.4m | ▲ 11.1% |
| Financial income75/76B | - | €1.6m | €1.4m | €457,853 | ▼ 67.6% |
| Recurring financial income75 | €32,844 | €1.6m | €1.4m | €457,853 | ▼ 67.6% |
| Income from current assets751 | - | €1.6m | €1.4m | €457,105 | ▼ 67.6% |
| Other financial income752/9 | - | €653 | €738 | €748 | ▲ 1.4% |
| Financial charges65/66B | - | €306,131 | €1.4m | €1.3m | ▼ 3.8% |
| Recurring financial charges65 | €30,365 | €306,131 | €1.4m | €1.3m | ▼ 3.8% |
| Debt charges650 | - | - | €59,681 | €55,381 | ▼ 7.2% |
| Other financial charges652/9 | - | €306,131 | €1.3m | €1.3m | ▼ 3.6% |
| Profit (loss) for the period before taxes9903 | €4.1m | €11.9m | €11.3m | €11.6m | ▲ 3.0% |
| Income taxes67/77 | €1.8m | €3.0m | €3.4m | €2.8m | ▼ 15.4% |
| Taxes670/3 | - | €3.3m | €3.4m | €2.8m | ▼ 15.4% |
| Tax adjustments and reversals of tax provisions77 | - | €297,992 | €0 | - | - |
| Profit (loss) for the period9904 | €2.3m | €8.9m | €7.9m | €8.7m | ▲ 10.9% |
| Transfer from tax-exempt reserves789 | - | - | €1.3m | - | - |
| Profit (loss) for the period to be appropriated9905 | €2.3m | €8.9m | €9.2m | €8.7m | ▼ 4.9% |
| Line | 2018 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Assets | |||||
| Total assets20/58 | €101.9m | €189.3m | €190.4m | €164.7m | ▼ 13.5% |
| Fixed assets21/28 | €11.7m | €8.9m | €8.3m | €6.4m | ▼ 22.5% |
| Tangible fixed assets22/27 | €11.7m | €8.9m | €8.3m | €6.4m | ▼ 22.5% |
| Land and buildings22 | - | €8.8m | €8.2m | €5.7m | ▼ 30.4% |
| Plant, machinery and equipment23 | - | €40,693 | €26,739 | €52,308 | ▲ 95.6% |
| Furniture and vehicles24 | - | €121,837 | €95,349 | €53,949 | ▼ 43.4% |
| Assets under construction and advance payments27 | - | - | - | €638,599 | - |
| Financial fixed assets28 | €13,885 | - | - | - | - |
| Current assets29/58 | €90.2m | €180.4m | €182.1m | €158.3m | ▼ 13.1% |
| Stocks and contracts in progress3 | €47.5m | €48.2m | €69.7m | €55.9m | ▼ 19.8% |
| Stocks30/36 | - | €48.2m | €69.7m | €55.9m | ▼ 19.8% |
| Goods purchased for resale34 | - | €48.2m | €69.7m | €55.9m | ▼ 19.8% |
| Amounts receivable within one year40/41 | €38.4m | €85.5m | €112.4m | €102.3m | ▼ 9.0% |
| Trade receivables40 | - | €55.1m | €71.0m | €65.8m | ▼ 7.3% |
| Other amounts receivable41 | - | €30.4m | €41.4m | €36.5m | ▼ 11.9% |
| Cash at bank and in hand54/58 | €4.1m | €46.6m | €0 | - | - |
| Deferred charges and accrued income490/1 | - | €7,460 | €33,784 | €82,612 | ▲ 145% |
| Equity and liabilities | |||||
| Total equity and liabilities10/49 | €101.9m | €189.3m | €190.4m | €164.7m | ▼ 13.5% |
| Equity10/15 | €41.8m | €69.8m | €55.7m | €64.5m | ▲ 15.7% |
| Contributions10/11 | €32.0m | €33.2m | €33.2m | €33.2m | = |
| Capital10 | - | €32.0m | €32.0m | €32.0m | = |
| Issued capital100 | - | €32.0m | €32.0m | €32.0m | = |
| Outside capital11 | - | €1.2m | €1.2m | €1.2m | = |
| Share premium1100/10 | - | €1.2m | €1.2m | €1.2m | = |
| Reserves13 | €3.8m | €5.3m | €5.3m | €5.3m | = |
| Non-distributable reserves130/1 | - | €3.2m | €3.2m | €3.2m | = |
| Legal reserve130 | - | €3.2m | €3.2m | €3.2m | = |
| Tax-exempt reserves132 | - | €1.3m | €0 | - | - |
| Distributable reserves133 | - | €780,865 | €2.1m | €2.1m | = |
| Profit (loss) carried forward14 | €4.7m | €31.3m | €17.2m | €25.9m | ▲ 50.8% |
| Provisions and deferred taxes16 | €15.1m | €4.7m | €4.6m | €2.5m | ▼ 45.1% |
| Provisions for liabilities and charges160/5 | - | €4.7m | €4.6m | €2.5m | ▼ 45.1% |
| Pensions and similar obligations160 | - | €4.6m | €4.5m | €2.4m | ▼ 47.4% |
| Other liabilities and charges164/5 | - | €113,913 | €113,913 | €168,148 | ▲ 47.6% |
| Amounts payable17/49 | €45.0m | €114.7m | €130.1m | €97.7m | ▼ 24.9% |
| Amounts payable within one year42/48 | €45.0m | €114.7m | €130.1m | €97.7m | ▼ 24.9% |
| Financial debts43 | - | - | €14.2m | €11.4m | ▼ 19.6% |
| Other loans439 | - | - | €14.2m | €11.4m | ▼ 19.6% |
| Trade debts44 | €24.1m | €106.5m | €84.7m | €77.8m | ▼ 8.2% |
| Suppliers440/4 | - | €106.5m | €84.7m | €77.8m | ▼ 8.2% |
| Taxes, remuneration and social security45 | - | €8.2m | €9.2m | €8.5m | ▼ 7.4% |
| Taxes450/3 | - | €1.0m | €1.2m | €691,352 | ▼ 40.1% |
| Remuneration and social security454/9 | - | €7.2m | €8.1m | €7.8m | ▼ 2.7% |
| Other amounts payable47/48 | - | - | €22.0m | €6,792 | ▼ 100.0% |
| Line | 2018 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €2.3m | €8.9m | €7.9m | €8.7m | ▲ 10.9% |
| + Depreciation and write-downs630 | €796,680 | €791,234 | €753,150 | €728,875 | ▼ 3.2% |
| Operating cash flow (approximation) | €3.1m | €9.7m | €8.6m | €9.5m | ▲ 9.6% |
| Investment in fixed assets (approximation) | - | - | -€107,314 | €1.1m | ▲ 1,158% |
| Change in cash | - | - | -€46.6m | - | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
27-08
State Gazette act
Resignation: Maria Johanna BORST (bestuurder)Appointment: Silvia BARCELEIRO (managing director) · Reappointments: I. JOERIN (director) and E. YOUSSEF (director) · Declaration37 facts ▸
State Gazette act
Resignation: Maria Johanna BORST (bestuurder)
Appointment: Silvia BARCELEIRO (managing director) · Reappointments: I. JOERIN (director) and E. YOUSSEF (director) · Declaration37 facts ▸
- Board meeting, 21-05-2026
- Declaration, delegatie van bevoegdheden door de raad van bestuur aan welbepaalde personen zoals voor datum van deze vergadering gepubliceerd in het Belgisch Staatsblad niet…
- Power of attorney, Fabrizio LONGHI
- Power of attorney, Nizar SEBTI
- Power of attorney, Luc VAN DRIESSCHE
- Power of attorney, Thomas LIMBEROPOULOS
- Power of attorney, Geert BUTSTRAEN
- Power of attorney, Stefaan FIERS
- Power of attorney, Julie PIESSEVAUX
- Power of attorney, Eva DE JONGH
- Power of attorney, Maria Johanna BORST
- Power of attorney, Silvia BARCELEIRO
- +25 further facts in this act
09-06
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
17-06
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
04-02
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 188 days late
2023
31-12
Financial
Highest result since 2018net €8.9m ▲285%
Net result €8.9m, the highest in the series.
31-12
Financial
Equity above €50mEq €69.8m ▲67.2%
2 profitable years in a row build equity to €69.8m.
09-05
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
29-04
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
28-04
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
07-05
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2019
29-04
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
03-05
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
28-04
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 48 acts read
About the unread acts
Of the 48 Belgian State Gazette acts we know for this company, 1 has been read. The other 47 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
under verification, last change in 2026
This board is reconstructed from a single act (26109187). A Gazette act generally publishes only CHANGES, not a full roll call, so directors unchanged since then may be missing here. The KBO register holds the complete list of function holders.
Day-to-day management 1
Silvia BARCELEIRO
Current(gedelegeerd) bestuurder · since 01-05-2026
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ.
See the function holders in the CBE →
Not every act has been read: a resignation may be missing here
47 of this company's 48 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Anderlecht · 2 establishment units since 1924
Ground area
2.1 ha
Building footprint
2,747 m²
Volume, LiDAR
48,418 m³
2 parcels, Brussels, Flanders · tallest building 26.6 m, ±7 floors. Linked by address, not a title deed.
3
companies at this address
See who is registered here
2 establishment units
Dantestraat 75, 1070 Anderlecht
since 19242.003.056.631
Berkenlaan 8A, 1831 Machelen (Brab.)
since 20252.378.693.287
2 parcels
Flanders
1
(50%)
Brussels
1
(50%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21306C0225/00C002 | Brussels | 1.2 ha | 1 · 1,356 m² | 19.1 m · 5 fl. |
| 23015B0120/00E000 | Flanders | 9,322 m² | 1 · 1,390 m² | 26.6 m · 7 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Mandate history
4 people since 2026, 3 in office
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| E. YOUSSEF |
|
| I. JOERIN |
|
| Silvia BARCELEIRO |
|
| Maria Johanna Borst |
|
Structure & network
Connections & network
3 current directorsThe group is listed under Ownership & control below; here you explore it as a network.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, scroll to zoom.
Ownership & control
1 board mandateBoard mandates of this companythis company sits on their board1
Public money · subsidies and aid
Flemish government
2022 to 2023 · 2 entries · 18,576 EUR awarded · 18,576 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2023 | 1 | 6,992 EUR | 6,992 EUR |
| 2022 | 1 | 11,584 EUR | 11,584 EUR |
Recognitions · licences · registrations
Legal Entity Identifier
54930036NIIQZPO7LM03
Similar companies · same sector, comparable size
LONZA VERVIERS
BE 0463.156.786
Verviers · Eq €62.4m
Novo Nordisk Production Belgium SA
BE 0465.935.738
Brussel · Eq €74.2m
ODYSSEA PHARMA
BE 0892.121.272
Grâce-Hollogne · Eq €76.4m
PHYSIOL
BE 0428.242.033
Liège · Eq €78.4m
BAXTER
BE 0403.093.693
Lessines · Eq €83.8m
Of 148 companies in sector 21201 we hold annual accounts for 116. 36 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded12-02-1924
Fiscal year end31-12
Activities, NACEBEL 2025
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
46460Wholesale of pharmaceutical and medical goods
20590Manufacture of chemicals and chemical products
Scores and ratios are computed by Checked and are not a credit decision.